TMX Newsfile·2026-03-04 22:54Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The lawsuit claims that Mereo provided misleading information regarding the expected results of its Phase 3 studies for setrusumab in Osteogenesis Imperfecta (OI) [5]. Group 2: Misleading Statements - The lawsuit alleges that Mereo made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs [6]. - Neither of the studies achieved their primary endpoints, which misled investors into purchasing Mereo's ADSs at inflated prices, resulting in damages when the true information was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and securing over $438 million for investors in 2019 [4].